Literature DB >> 10903223

The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.

E Israel1, J M Drazen, S B Liggett, H A Boushey, R M Cherniack, V M Chinchilli, D M Cooper, J V Fahy, J E Fish, J G Ford, M Kraft, S Kunselman, S C Lazarus, R F Lemanske, R J Martin, D E McLean, S P Peters, E K Silverman, C A Sorkness, S J Szefler, S T Weiss, C N Yandava.   

Abstract

Inhaled beta-adrenergic agonists are the most commonly used medications for the treatment of asthma although there is evidence that regular use may produce adverse effects in some patients. Polymorphisms of the beta(2)-adrenergic receptor (beta(2)-AR) can affect regulation of the receptor. Smaller studies examining the effects of such polymorphisms on the response to beta-agonist therapy have produced inconsistent results. We examined whether polymorphisms at codon 16 (beta(2)-AR-16) and codon 27 (beta(2)-AR-27) of the beta(2)-AR might affect the response to regular versus as-needed use of albuterol by genotyping the 190 asthmatics who had participated in a trial examining the effects of regular versus as needed albuterol use. During the 16-wk treatment period there was a small decline in morning peak expiratory flow in patients homozygous for arginine at B(2)-AR-16 (Arg/Arg) who used albuterol regularly. This effect was magnified during a 4-wk run out period, during which all patients returned to using as-needed albuterol, so that by the end of the study Arg Arg patients who had regularly used albuterol had a morning peak expiratory flow 30. 5 +/- 12.1 L/min lower (p = 0.012) than Arg/Arg patients who had used albuterol on an as needed basis. There was no decline in peak flow with regular use of albuterol in patients who were homozygous for glycine at beta(2)-AR-16. Evening peak expiratory flow also declined in the Arg/Arg patients who used albuterol regularly but not in those who used albuterol on an as-needed basis. No significant differences in outcomes between regular and as-needed treatment were associated with polymorphisms at position 27 of the beta(2)-AR. No other differences in asthma outcomes that we investigated occurred in relation to these beta(2)-AR polymorphisms. Polymorphisms of the beta(2)-AR may influence airway responses to regular inhaled beta-agonist treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903223     DOI: 10.1164/ajrccm.162.1.9907092

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  124 in total

1.  Bayesian haplotype inference for multiple linked single-nucleotide polymorphisms.

Authors:  Tianhua Niu; Zhaohui S Qin; Xiping Xu; Jun S Liu
Journal:  Am J Hum Genet       Date:  2001-11-26       Impact factor: 11.025

2.  Assessing the cost-effectiveness of pharmacogenomics.

Authors:  D L Veenstra; M K Higashi; K A Phillips
Journal:  AAPS PharmSci       Date:  2000

Review 3.  Candidate gene case-control association studies: advantages and potential pitfalls.

Authors:  A K Daly; C P Day
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

Review 4.  Management of asthma in adults: current therapy and future directions.

Authors:  R H Green; C E Brightling; I D Pavord; A J Wardlaw
Journal:  Postgrad Med J       Date:  2003-05       Impact factor: 2.401

5.  Long-acting beta agonists in asthma therapy.

Authors:  Richard W Rissmiller; Michael J Larj; Stephen P Peters
Journal:  Curr Allergy Asthma Rep       Date:  2004-03       Impact factor: 4.806

Review 6.  Beta-agonists and asthma: too much of a good thing?

Authors:  Stephanie A Shore; Jeffrey M Drazen
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

Review 7.  Antagonism of long-acting beta2-adrenoceptor agonism.

Authors:  Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

8.  Polymorphisms of cardiac presynaptic alpha2C adrenergic receptors: Diverse intragenic variability with haplotype-specific functional effects.

Authors:  Kersten M Small; Jeanne Mialet-Perez; Carrie A Seman; Cheryl T Theiss; Kari M Brown; Stephen B Liggett
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-19       Impact factor: 11.205

Review 9.  Pharmacogenetics of asthma.

Authors:  John J Lima; Kathryn V Blake; Kelan G Tantisira; Scott T Weiss
Journal:  Curr Opin Pulm Med       Date:  2009-01       Impact factor: 3.155

Review 10.  Pharmacogenetics of the beta 2-adrenergic receptor gene.

Authors:  Victor E Ortega; Gregory A Hawkins; Stephen P Peters; Eugene R Bleecker
Journal:  Immunol Allergy Clin North Am       Date:  2007-11       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.